DISC MEDICINE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.17 USD | +6.11% |
|
+4.11% | -42.57% |
| May. 09 | Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 08 | Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 336.6 | 1,394 | 820 | - | - |
| Enterprise Value (EV) 1 | 142 | 1,394 | 455.2 | 461.6 | 509.6 |
| P/E ratio | -0.44 x | -16.9 x | -7.03 x | -6.11 x | -5.02 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 256 x |
| EV / Revenue | - | - | - | - | 159 x |
| EV / EBITDA | - | -15.3 x | -3.45 x | -2.82 x | -2.87 x |
| EV / FCF | - | - | -4.06 x | -4.2 x | -3.71 x |
| FCF Yield | - | - | -24.6% | -23.8% | -27% |
| Price to Book | - | - | 2.23 x | 2.13 x | 3.24 x |
| Nbr of stocks (in thousands) | 16,923 | 24,140 | 24,722 | - | - |
| Reference price 2 | 19.89 | 57.76 | 33.17 | 33.17 | 33.17 |
| Announcement Date | 3/31/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 3.2 |
| EBITDA 1 | - | - | -91.02 | -132 | -163.6 | -177.3 |
| EBIT 1 | - | -47.48 | -91.12 | -142.4 | -152.8 | -177.1 |
| Operating Margin | - | - | - | - | - | -5,535.5% |
| Earnings before Tax (EBT) 1 | - | -46.83 | -76.33 | -119.4 | -143.4 | -168 |
| Net income 1 | -35.97 | -46.83 | -76.43 | -119 | -145 | -182 |
| Net margin | - | - | - | - | - | -5,686.98% |
| EPS 2 | -4.490 | -45.05 | -3.420 | -4.719 | -5.432 | -6.606 |
| Free Cash Flow 1 | - | - | - | -112 | -110 | -137.3 |
| FCF margin | - | - | - | - | - | -4,291.67% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/2/22 | 3/31/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -15.02 | -25.12 | -17.33 | -18.96 | -29.71 | -31.46 | -31.27 | -31.68 | -34.93 | -37.8 | -35.25 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -11.24 | -22.76 | -15.92 | -14.1 | -23.55 | -26.94 | -29.46 | -29.88 | -33.13 | -37.8 | -35.25 |
| Net income 1 | -16.15 | -11.24 | -22.78 | -15.95 | -14.12 | -23.58 | -26.95 | -29.35 | -29.81 | -32.94 | -37.8 | -35.25 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.860 | -40.91 | -1.200 | -0.7400 | -0.5800 | -0.9700 | -1.090 | -1.181 | -1.197 | -1.259 | -1.340 | -1.360 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/23/22 | 3/31/23 | 5/15/23 | 8/11/23 | 11/9/23 | 3/21/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 195 | - | 365 | 358 | 310 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -112 | -110 | -137 |
| ROE (net income / shareholders' equity) | - | - | - | -30.3% | -31.8% | -36.3% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | 14.90 | 15.60 | 10.30 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 0.15 | - | 0.15 | 2.55 | 5.05 |
| Capex / Sales | - | - | - | - | - | 157.81% |
| Announcement Date | 9/2/22 | 3/31/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
33.17
USD
Average target price
57.33
USD
Spread / Average Target
+72.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.57% | 820M | |
| +64.23% | 62.59B | |
| -2.31% | 41.18B | |
| +45.49% | 40.29B | |
| -8.29% | 27.9B | |
| +11.97% | 26.21B | |
| -21.16% | 19.09B | |
| +7.54% | 13.08B | |
| +27.17% | 12.05B | |
| +25.72% | 12.26B |
- Stock Market
- Equities
- IRON Stock
- Financials Disc Medicine, Inc.
